MedTrace Logo

Stereotactic Body Radiation Therapy (SBRT) for Liver Mets

NCT01360606 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2024-10-10

Study results available
· View outcomes & findings →

Summary

This is a phase I dose escalation study. Dose escalation will be via the traditional "up and down" scheme. SBRT:

Patients will receive one of the following radiation regimens:

* 50 Gy in 5 fractions (10 Gy/fx) delivered over a 2-week period.
* 60 Gy in 5 fractions (12 Gy/fx) delivered over a 2-week period.
* 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period.

Conditions

  • Liver Metastases

Interventions

RADIATION

Stereotactic Body Radiation Therapy

SBRT: Patients will receive one of the following radiation regimens: * 50 Gy in 5 fractions (10 Gy/fx) delivered over a 2-week period. * 60 Gy in 5 fractions (12 Gy/fx) delivered over a 2-week period. * 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period.

Sponsors & Collaborators

  • Susannah Ellsworth

    lead OTHER

Principal Investigators

  • Susannah Ellsworth, MD · UPMC Hillman Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-03-23
Primary Completion
2018-07-25
Completion
2021-02-04
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01360606 on ClinicalTrials.gov